Reimagining Medicine
Company overview
Financial review
Conclusions
Appendix
References
contributing to core margin improvements for Group
Net sales
change vs. PY1
(in % cc)
Innovative Medicines
9
Sandoz
Q2 2023
Core operating
income
change vs. PY1
(in % cc)
Core
margin¹
(%)
Core margin
change vs. PY1
(%pts cc)
Net sales
change vs. PY1
(in % cc)
20
39.0
3.4
8
FINANCIAL PROFILE
H1 2023
Core operating
income
change vs. PY1
(in % cc)
Core
margin¹
(%)
Core margin
change vs. PY1
(%pts cc)
19
38.9
3.6
8
6
18.0
-0.3
8
5
19.6
-0.5
Group
9
17
34.3
2.5
8
16
34.2
2.4
Novartis ex-Sandoz
9
19
37.7
3.0
8
18
37.4
3.0
1. Constant currencies (cc), core results are non-IFRS measures. An explanation of non-IFRS measures can be found on page 48 of the Condensed Interim Financial Report.
20 Investor Relations | Q2 2023 Results
✓ NOVARTIS | Reimagining MedicineView entire presentation